These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 33843252)

  • 21. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
    Foster SA; Zhu B; Guo J; Nikai E; Ojeh C; Malatestinic W; Goldblum O; Kornberg LJ; Wu JJ
    J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial.
    Holt RIG; Gossage-Worrall R; Hind D; Bradburn MJ; McCrone P; Morris T; Edwardson C; Barnard K; Carey ME; Davies MJ; Dickens CM; Doherty Y; Etherington A; French P; Gaughran F; Greenwood KE; Kalidindi S; Khunti K; Laugharne R; Pendlebury J; Rathod S; Saxon D; Shiers D; Siddiqi N; Swaby EA; Waller G; Wright S
    Br J Psychiatry; 2019 Feb; 214(2):63-73. PubMed ID: 30251622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
    Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
    [No Abstract]   [Full Text] [Related]  

  • 25. Assessment of racial and ethnic inequities in copay card utilization and enrollment in copay adjustment programs.
    Ingham M; Sadik K; Zhao X; Song J; Fendrick AM
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1084-1092. PubMed ID: 37548953
    [No Abstract]   [Full Text] [Related]  

  • 26. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.
    Malatestinic W; Nordstrom B; Wu JJ; Goldblum O; Solotkin K; Lin CY; Kistler K; Fraeman K; Johnston J; Hawley LL; Sicignano N; Araujo A
    J Manag Care Spec Pharm; 2017 Mar; 23(3):370-381. PubMed ID: 28230450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of gilteritinib for relapsed/refractory
    Pandya BJ; Qi CZ; Garnham A; Yang H; Shah MV; Zeidan AM
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1469-1481. PubMed ID: 34595955
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
    Sanchez L; Chari A; Cheng M; Cherepanov D; DerSarkissian M; Huang F; Stull DM; Dabora J; Young M; Noga SJ; Pi S; Zhang M; Banatwala A; Duh MS; Ailawadhi S
    J Manag Care Spec Pharm; 2023 Nov; 29(11):1205-1218. PubMed ID: 37776124
    [No Abstract]   [Full Text] [Related]  

  • 29. A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.
    McCormick D; Bhatt DL; Bays HE; Taub PR; Caldwell KA; Guerin CK; Steinhoff J; Ahmad Z; Singh R; Moreo K; Carter J; Heggen CL; Sapir T
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1517-1528. PubMed ID: 33251993
    [No Abstract]   [Full Text] [Related]  

  • 30. Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk.
    Lin I; Sung J; Sanchez RJ; Mallya UG; Friedman M; Panaccio M; Koren A; Neumann P; Menzin J
    J Manag Care Spec Pharm; 2016 Jun; 22(6):685-98. PubMed ID: 27231796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance.
    Zhang J; Sridhar G; Barr CE; Eichelberger B; Lockhart CM; Marshall J; Clewell J; Accortt NA; Curtis JR; Holmes C; McMahill-Walraven CN; Brown JS; Haynes K
    J Manag Care Spec Pharm; 2020 Apr; 26(4):417-490. PubMed ID: 32223608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic burden related to fistulas or strictures among commercially insured patients with Crohn's disease in the United States.
    Fan Y; Zhang L; Jiménez MC; Bohn RL; Thompson JS; Brodovicz KG; Gray S; Melmed GY
    J Manag Care Spec Pharm; 2023 Apr; 29(4):400-408. PubMed ID: 36989446
    [No Abstract]   [Full Text] [Related]  

  • 33. Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis.
    Mooney J; Reddy SR; Chang E; Broder MS; Gokhale S; Corral M
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1724-1733. PubMed ID: 34818092
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis.
    Hutson TE; Liu FX; Dieyi C; Kim R; Krulewicz S; Kasturi V; Bhanegaonkar A
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1171-1181. PubMed ID: 34165322
    [No Abstract]   [Full Text] [Related]  

  • 35. A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.
    Diamond MP; Stewart EA; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
    Hum Reprod Open; 2019; 2019(4):hoz027. PubMed ID: 31777761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of dyskalemias with short-term health care utilization in patients with advanced CKD.
    Dashputre AA; Gatwood J; Sumida K; Thomas F; Akbilgic O; Potukuchi PK; Obi Y; Molnar MZ; Streja E; Kalantar-Zadeh K; Kovesdy CP
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1403-1415. PubMed ID: 34595956
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of financial medication assistance on medication adherence: a systematic review.
    Hung A; Blalock DV; Miller J; McDermott J; Wessler H; Oakes MM; Reed SD; Bosworth HB; Zullig LL
    J Manag Care Spec Pharm; 2021 Jul; 27(7):924-935. PubMed ID: 34185554
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study.
    Marshall JK; Bessette L; Thorne C; Shear NH; Lebovic G; Gerega SK; Millson B; Oraichi D; Gaetano T; Gazel S; Latour MG; Laliberté MC
    Clin Ther; 2018 Mar; 40(3):415-429.e6. PubMed ID: 29519714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using Previous Medication Adherence to Predict Future Adherence.
    Kumamaru H; Lee MP; Choudhry NK; Dong YH; Krumme AA; Khan N; Brill G; Kohsaka S; Miyata H; Schneeweiss S; Gagne JJ
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1146-1155. PubMed ID: 30362915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study.
    Srulovici E; Garg V; Ghilai A; Feldman B; Hoshen M; Balicer RD; Skup M; Leventer-Roberts M
    Adv Ther; 2018 May; 35(5):655-665. PubMed ID: 29748914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.